RayzeBio, Inc. Common Stock (RYZB) Research

RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.

Market snapshot

Symbol
RYZB
Price
$62.49
Day change
+0.02%
Market cap
$3.8B
P/E ratio
-35.73x
52-week range
17.95-62.51
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Alpine Immune Sciences, Inc. (ALPN)
  • CymaBay Therapeutics, Inc. (CBAY)
  • Chinook Therapeutics, Inc. (KDNY)
  • MorphoSys AG (MOR)
  • Morphic Holding, Inc. (MORF)
  • Mirati Therapeutics, Inc. (MRTX)
  • Myovant Sciences Ltd. (MYOV)
  • 1Life Healthcare, Inc. (ONEM)

Recent insider activity

  • VIKING GLOBAL INVESTORS LP — J-Other (1743556 shares) on 2024-02-26
  • Redmile Group, LLC — C-Conversion (498510 shares) on 2023-09-19
  • Redmile Group, LLC — C-Conversion (494687 shares) on 2023-09-19
  • Redmile Group, LLC — C-Conversion (864509 shares) on 2023-09-19
  • Redmile Group, LLC — C-Conversion (864509 shares) on 2023-09-19

Open RayzeBio, Inc. Common Stock (RYZB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.